News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Investor Alerts Year All Years 2023 2022 2021 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard May 30, 2023 Immunic to Participate in Scientific and Investor Conferences in June May 17, 2023 Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis May 11, 2023 Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update May 9, 2023 Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update May 6, 2023 Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action May 4, 2023 Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders Apr 27, 2023 Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. Apr 26, 2023 Immunic to Participate in Investor and Scientific Conferences in May Apr 5, 2023 Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Mar 2, 2023 Immunic to Participate in Investor and Scientific Conferences in March Show 5102550100 per page«123456789…16»
